Literature DB >> 24867828

Symptomatic treatment of migraine: from scientific evidence to patient management.

Gian Camillo Manzoni1, P Torelli.   

Abstract

All migraine patients need symptomatic treatment to stop individual attacks or, at least, significantly relieve pain. When attacks are very frequent (more than 3 days of headache per month on average), they will also need preventive treatment. The first physician the patient must address to for preventive treatment is the general practitioner (GP). If the medication prescribed by the GP is not effective or there is overuse of symptomatic drugs, the patient will have to be referred to a neurologist or a headache clinic. The drugs to be used as symptomatic treatment are triptans and non-steroidal anti-inflammatory drugs. Combination therapy with antiemetics is also important. While specialists will base their therapeutic decisions on guidelines in the literature and on their personal experience, GPs do not yet have any easy-to-use tools to support them. To fill this gap, an algorithm is proposed here that can be easily used by GPs to make decisions during their patients' migraine attacks.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24867828     DOI: 10.1007/s10072-014-1734-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  9 in total

Review 1.  A redefinition of primary headache: chronic migraine.

Authors:  P Torelli; G C Manzoni
Journal:  Neurol Sci       Date:  2012-05       Impact factor: 3.307

Review 2.  ICHD-3: what changes do we need regarding migraine?

Authors:  Gian Camillo Manzoni; Ilaria Grisendi; Paola Torelli
Journal:  Curr Pain Headache Rep       Date:  2011-06

3.  Optimal use of acute headache medication: a qualitative examination of behaviors and barriers to their performance.

Authors:  Elizabeth K Seng; Kenneth A Holroyd
Journal:  Headache       Date:  2013-06-28       Impact factor: 5.887

4.  Description and validation of an Italian ICHD-II-based questionnaire for use in epidemiological research.

Authors:  Giorgia Abrignani; Tullia Ferrante; Paola Castellini; Giorgio Lambru; Ettore Beghi; Gian Camillo Manzoni; Paola Torelli
Journal:  Headache       Date:  2011-12-28       Impact factor: 5.887

Review 5.  Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.

Authors:  S D Silberstein; S Holland; F Freitag; D W Dodick; C Argoff; E Ashman
Journal:  Neurology       Date:  2012-04-24       Impact factor: 9.910

6.  Medical consultation for migraine: results from the American Migraine Study.

Authors:  R B Lipton; W F Stewart; D Simon
Journal:  Headache       Date:  1998-02       Impact factor: 5.887

7.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

8.  Proposals for the organisation of headache services in Europe.

Authors:  Fabio Antonaci; Dominique Valade; Michel Lanteri-Minet; José Miguel Láinez; Rigmor Jensen; Timothy J Steiner
Journal:  Intern Emerg Med       Date:  2008-10       Impact factor: 3.397

9.  A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department.

Authors:  Mark A Kostic; Francisco J Gutierrez; Thomas S Rieg; Tammy S Moore; Richard T Gendron
Journal:  Ann Emerg Med       Date:  2010-01-04       Impact factor: 5.721

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.